Welcome to our dedicated page for Aardvark Therapeutics SEC filings (Ticker: AARD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aardvark Therapeutics, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing small-molecule therapies for metabolic diseases. Recent 8-K reports cover financial results, pipeline and business updates, ARD-101 HERO trial disclosures in Prader-Willi Syndrome, ARD-201 obesity program updates, clinical protocol matters, and corporate presentation materials.
The filing record also includes capital-structure disclosures tied to a shelf registration statement and equity distribution agreement, governance and executive-transition matters, compensatory arrangements, and the role of Ardia Therapeutics as a wholly owned subsidiary supporting Aardvark's dermatology pipeline.
Aardvark Therapeutics filed a Form 144 reporting a proposed sale of 27,691 common shares on NASDAQ with an aggregate market value of $241,565.21. The shares represent a small portion of the company’s listed outstanding shares (21,696,893). The filer acquired the shares on 05/16/2019 in a private acquisition from the issuer and paid cash. No securities were reported sold by the same person in the past three months. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Aardvark Therapeutics, Inc. filed a Form S-8 to register securities under the 2025 Inducement Equity Incentive Plan, making the plan documents and related stock award agreements part of the company's registration record. The filing incorporates by reference the company's recent annual and quarterly reports, a current report and the description of its common stock, so those reports together form the prospectus for employees and other plan participants.
The registrant indicates it is a non-accelerated filer, a smaller reporting company and an emerging growth company. The company describes its charter and bylaw provisions that limit director and officer monetary liability to the fullest extent permitted by Delaware law and details indemnification rights, advancement of expenses, and indemnification agreements with directors and executive officers. The filing also states that the company maintains insurance covering directors and officers for certain wrongful acts.
Exhibits listed include the Amended and Restated Certificate of Incorporation and Bylaws, the 2025 Inducement Equity Incentive Plan and forms of award agreements, legal opinion and accounting and counsel consents, and a filing fee table. The text provided does not include offering size, pricing or detailed financial terms of the awards in this extract.
Aardvark Therapeutics is a clinical-stage biopharmaceutical company focused on TAS2R-targeting small molecules to treat hunger-associated metabolic diseases. The company has initiated a potentially pivotal Phase 3 HERO trial for its lead candidate ARD-101 (enrollment began in Q2 2025) and submitted a protocol amendment in August 2025 to broaden eligibility (removing certain exclusions and adding patients under age 13), and expects HERO topline data in Q3 2026. The company also plans Phase 2 programs: HONOR (HO) in H2 2025, POWER in H2 2025 and STRENGTH in H1 2026.
On the balance sheet, Aardvark completed an IPO in February 2025 (6,120,661 shares at $16.00) and had combined cash, cash equivalents and short-term investments of $141.8 million at June 30, 2025, which management believes is sufficient for at least one year. Operating losses widened to a $14.4 million net loss for the three months ended June 30, 2025 (six months: $23.7 million), an accumulated deficit of $82.0 million, and six-month operating cash use of $21.2 million. The company discloses potential milestone obligations totaling $180.5 million and a written-off related-party receivable of $2.368 million.
Aardvark Therapeutics, Inc. reported that it issued a press release on August 13, 2025 detailing its financial results for the second quarter ended June 30, 2025, along with updates on its drug development pipeline and overall business. The press release is provided as Exhibit 99.1 and gives the full results and operational commentary.
The company specifies that this press release and related information are being furnished rather than filed, meaning they are not subject to certain legal liabilities under the Securities Exchange Act and are not automatically incorporated into other securities law documents unless specifically referenced.
Aardvark Therapeutics disclosed via this Current Report that it issued a press release announcing new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. The company states the full text of the press release is filed as Exhibit 99.1 to the report and is incorporated by reference.
The filing does not include clinical data, quantitative results, financial statements, or a timetable for next steps; the report also identifies the registrant as an emerging growth company. Consult Exhibit 99.1 for the full press release text and any data not contained in the 8-K.